Clinical trial
Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for…
NCT00291811 · Genzyme, a Sanofi Company, Industry · Approved for marketing
Key facts
| NCT number | NCT00291811 |
|---|---|
| Title | Access Program for Use of AMD3100 to Increase Peripheral Blood Stem Cells for Transplantation in Patients Who Have Failed Standard Therapy Stem Cell Mobilization |
| Official title | Compassionate Use Protocol for the Use of AMD3100 to Mobilize Peripheral Blood Stem Cells for Collection and Transplantation |
| Acronym | CUP |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Approved for marketing |
| Study type | Expanded Access |
| Conditions | Autologous Stem Cell Transplant |
| Intervention type | Drug |
| Interventions | AMD3100 + G-CSF |
| Start date | Oct 1, 2003 |
| First posted | Feb 15, 2006 |
| Last update posted | Feb 11, 2014 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: